anti ctsl antibody (R&D Systems)
Structured Review
Anti Ctsl Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 23 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cathepsin+l/Insect+Cathepsin+L+Antibody/bio_rxiv__64898__2026__04__16__719038-141-7-11
Average 94 stars, based on 23 article reviews
Images
Related Articles
Incubation:Article Title: Repurposing mesalamine for acute kidney injury through supramolecular assembly. Article Snippet: Acute kidney injury (AKI) is a prevalent and life-threatening condition, particularly in patients undergoing highrisk surgeries, where the incidence can exceed 50 %.. Despite its growing impact, therapeutic options remain limited, with dialysis being the primary treatment.. Drug repurposing offers a better risk-versus-reward trade-off for accelerating the development of effective therapies. Article Title: Preclinical profiling of antibody drug conjugates targeting oncofetal chondroitin sulfate. Article Snippet: .. For cathepsin B and L digestion of ADCs and CDCs, enzyme was incubated with drug conjugate at a ratio of 1:1000 enzyme:drug conjugate for Cathepsin B (R&D Systems, #953-CY) and 1:40000 for Article Title: Preclinical profiling of antibody drug conjugates targeting oncofetal chondroitin sulfate Article Snippet: .. For cathepsin B and L digestion of ADCs and CDCs, enzyme was incubated with drug conjugate at a ratio of 1:1000 enzyme:drug conjugate for Cathepsin B (R&D Systems, #953-CY) and 1:40,000 for High Performance Liquid Chromatography:Article Title: Repurposing mesalamine for acute kidney injury through supramolecular assembly. Article Snippet: Acute kidney injury (AKI) is a prevalent and life-threatening condition, particularly in patients undergoing highrisk surgeries, where the incidence can exceed 50 %.. Despite its growing impact, therapeutic options remain limited, with dialysis being the primary treatment.. Drug repurposing offers a better risk-versus-reward trade-off for accelerating the development of effective therapies. Enzyme-linked Immunosorbent Assay:Article Title: Identification of serum protein biomarkers in individuals with Niemann-Pick disease, type C1 Article Snippet: .. Serum samples were thawed on ice and diluted in sample diluent and assayed in duplicate according to the manufacturer’s protocol as follows: TREM2 (Abcam, ab224881, Waltham MA, USA), AgRP (Human AgRP ELISA kit, ELH-AgRP-1, RayBiotech, Peachtree Corners, GA, USA), NPY (Human Neuropeptide Y/NPY DuoSet ELISA, DY8517-05, R&D Systems, Minneapolis, MN, USA), HSD17B14 (Human HSD17B14 PharmGenie ELISA kit, SBRS0680, Dublin, Ireland), GPNMB (Human Osteoactivin (GPNMB) ELISA kit, EHGPNMB, Invitrogen, Waltham, MA, USA), Binding Assay:Article Title: The G2019S LRRK2 mutation exacerbates α-synuclein and tau neuropathology through divergent pathways in Parkinson’s disease models Article Snippet: Proteins were subsequently transferred onto polyvinylidene fluoride (PVDF) membrane (Bio-Rad, 1,620,174) and analysed by immunoblotting. .. Nonspecific binding sites were blocked for 1 h at RT in 5% non-fat milk in PBS-T for 1 h at RT and probed overnight at 4 °C with the following primary antibodies: total αSyn C20 (rabbit, sc-7011-R, Santa Cruz, 1:1000); anti-pS129 αSyn (rabbit, Abcam, ab51253, 1:1000); LAMP2A (rabbit, Abcam, ab18528, 1:500); LAMP1 (rabbit, Abcam, ab24170, 1:1000); GBA (rabbit, Sigma-Aldrich, G4171, 1:1000); Cathepsin D (rabbit, Cell Signalling, 2284, 1:1000); Cathepsin B (mouse, Abcam, ab58802, 1:500); Cathepsin H (goat, R&D systems, AF1013, 1:2000); |

